We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

737 hedge funds and large institutions have $21.8B invested in Teva Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 119 funds opening new positions, 239 increasing their positions, 303 reducing their positions, and 164 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.23% more ownership

Funds ownership: 56.04% → 59.27% (+3.2%)

7% less funds holding

Funds holding: 795 → 737 (-58)

16% less capital invested

Capital invested by funds: $26B → $21.8B (-$4.23B)

21% less repeat investments, than reductions

Existing positions increased: 239 | Existing positions reduced: 303

23% less funds holding in top 10

Funds holding in top 10: 35 → 27 (-8)

27% less first-time investments, than exits

New positions opened: 119 | Existing positions closed: 164

33% less call options, than puts

Call options by funds: $433M | Put options by funds: $645M

Holders
737
Holders Change
-58
Holders Change %
-7.3%
% of All Funds
18.43%
Holding in Top 10
27
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-22.86%
% of All Funds
0.68%
New
119
Increased
239
Reduced
303
Closed
164
Calls
$433M
Puts
$645M
Net Calls
-$212M
Net Calls Change
-$188M

Top Buyers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
+$939M
2
BIT
BlackRock Institutional Trust
California
+$502M
3
Franklin Resources
Franklin Resources
California
+$390M
4
HCM
Highfields Capital Management
Massachusetts
+$347M
5
BFA
BlackRock Fund Advisors
California
+$289M

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$906M
2
PC
PointState Capital
New York
-$416M
3
Lazard Asset Management
Lazard Asset Management
New York
-$285M
4
WRF
Waddell & Reed Financial
Kansas
-$265M
5
BA
BlackRock Advisors
Delaware
-$186M
Name Holding Trade Value Shares
Change 		Change in
Stake
AL
801
AJO LP
Pennsylvania
– -$1.3M -28,225 Closed
NI
802
Numeric Investors
Massachusetts
– -$1.22M -26,400 Closed
FAM
803
Fred Alger Management
New York
– -$1.2M -25,970 Closed
BNP Paribas Asset Management
804
BNP Paribas Asset Management
France
– -$1.17M -25,521 Closed
BCM
805
BlueCrest Capital Management
Jersey
– -$998K -25,000 Closed
BCM
806
Bayesian Capital Management
New York
– -$1.13M -24,655 Closed
SSA
807
Schonfeld Strategic Advisors
New York
– -$1.1M -23,862 Closed
PAM
808
Princeton Alpha Management
New Jersey
– -$1.06M -23,041 Closed
JIR
809
James Investment Research
Ohio
– -$918K -19,959 Closed
RMSCM
810
R.M. Sincerbeaux Capital Management
New York
– -$900K -19,560 Closed
AB
811
AT Bancorp
Iowa
– -$861K -18,727 Closed
FWM
812
Frontier Wealth Management
Missouri
– -$836K -18,160 Closed
NO
813
Ninety One
South Africa
– -$823K -17,888 Closed
DC
814
Deere & Company
Illinois
– -$754K -16,382 Closed
TI
815
Turner Investments
Pennsylvania
– -$709K -15,400 Closed
GCP
816
GSA Capital Partners
United Kingdom
– -$705K -15,322 Closed
P
817
Pitcairn
Pennsylvania
– -$635K -13,790 Closed
HT
818
HAP Trading
New York
– -$535K -13,392 Closed
HCA
819
Harbour Capital Advisors
Virginia
– -$603K -13,110 Closed
BAS
820
Brown Advisory Securities
Maryland
– -$581K -12,651 Closed
DIA
821
Denver Investment Advisors
Colorado
– -$571K -12,417 Closed
WKWM
822
Walter & Keenan Wealth Management
Indiana
– -$561K -12,200 Closed
TI
823
Trexquant Investment
Connecticut
– -$543K -11,800 Closed
ACM
824
Argentus Capital Management
Texas
– -$531K -11,537 Closed
SAM
825
Silvercrest Asset Management
New York
– -$509K -11,069 Closed
31 32
33
34 35

TEVA Hedge Fund Activity: Q4 2016 in Review

737 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2016, worth a combined $21.8B — down 16% from $26B a quarter earlier.

Sellers outnumbered buyers: 164 funds closed out of TEVA and 119 opened new positions — a net loss of 45 holders — while 303 trimmed existing stakes and 239 added.

The largest buyer was Capital Research Global Investors, adding an estimated $939M. The largest seller was Viking Global Investors, exiting entirely with an estimated $906M sold.

  • 737 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2016, down from 795 in Q3 2016.
  • Funds reported $21.8B of Teva Pharmaceuticals stock for Q4 2016, down 16% quarter-over-quarter.
  • 119 funds opened new Teva Pharmaceuticals positions in Q4 2016 and 164 closed out, a net change of -45 holders.
  • The largest Teva Pharmaceuticals buyer in Q4 2016 was Capital Research Global Investors, an estimated $939M added.
  • The largest Teva Pharmaceuticals seller in Q4 2016 was Viking Global Investors, an estimated $906M sold.

Based on aggregated 13F filings for Q4 2016.